Synagis

E474951

Synagis is a monoclonal antibody medication used to help prevent serious lower respiratory tract infections caused by respiratory syncytial virus (RSV) in high-risk infants and young children.

All labels observed (2)

Label Occurrences
Synagis canonical 3
palivizumab 1

How this entity was disambiguated

Statements (49)

Predicate Object
instanceOf biologic drug ⓘ
medication ⓘ
monoclonal antibody ⓘ
bindsTo RSV F protein ⓘ
hasActiveIngredient palivizumab ⓘ
hasApprovalYear 1998 ⓘ
hasATCCode J06BB16 ⓘ
hasBrandName Synagis ⓘ
hasDosage 15 mg/kg once monthly ⓘ
hasFormulation solution for injection ⓘ
hasGenericName palivizumab ⓘ
linked to: Synagis
hasIndication prevention of RSV disease in high-risk infants ⓘ
prevention of RSV disease in high-risk young children ⓘ
prevention of serious lower respiratory tract infection caused by respiratory syncytial virus ⓘ
hasLegalStatus prescription only ⓘ
hasMechanismOfAction neutralizes respiratory syncytial virus and inhibits fusion with host cells ⓘ
hasMolecularType humanized monoclonal antibody ⓘ
hasPharmacologicClass antiviral monoclonal antibody ⓘ
immunologic agent ⓘ
hasPregnancyCategory not established for use in pregnancy ⓘ
hasRouteOfAdministration intramuscular ⓘ
parenteral ⓘ
hasSeriousAdverseEffect anaphylaxis ⓘ
severe hypersensitivity reaction ⓘ
hasSideEffect fever ⓘ
injection site reactions ⓘ
rash ⓘ
upper respiratory tract infection ⓘ
hasTargetPopulation high-risk infants ⓘ
high-risk young children ⓘ
isAdministeredAs monthly intramuscular injection during RSV season ⓘ
isAdministeredBy healthcare professional ⓘ
isAdministeredDuring RSV season ⓘ
isApprovedBy U.S. Food and Drug Administration ⓘ
isContraindicatedIn patients with history of severe hypersensitivity to palivizumab ⓘ
isGivenBy intramuscular injection into anterolateral thigh ⓘ
isIndicatedFor certain high-risk children up to 24 months of age ⓘ
infants with chronic lung disease of prematurity ⓘ
infants with hemodynamically significant congenital heart disease ⓘ
premature infants ⓘ
isMarketedBy AstraZeneca ⓘ
isNotRecommendedFor routine use in healthy full-term infants ⓘ
isNotUsedFor treatment of acute RSV disease ⓘ
treatment of established RSV infection ⓘ
isProducedBy recombinant DNA technology ⓘ
isUsedFor prophylaxis of RSV infection ⓘ
reduces risk of RSV-related hospitalization in high-risk infants ⓘ
targets respiratory syncytial virus ⓘ
wasDevelopedBy MedImmune ⓘ

How these facts were elicited

Referenced by (4)

Full triples — surface form annotated when it differs from this entity's canonical label.

MedImmune → notableProduct → Synagis ⓘ
MedImmune → developed → Synagis ⓘ
Synagis → hasGenericName → palivizumab ⓘ
linked to: Synagis
Synagis → hasBrandName → Synagis ⓘ